Found 9 clinical trials
IGFBP-3 in Ovarian Cancer Invasion
An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities
- 1 views
- 07 Nov, 2020
- 1 location
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. …
- 0 views
- 24 Sep, 2021
- 20 locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …
- 6055 views
- 02 Dec, 2021
- 820 locations
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
This is a large, prospective, single-arm cohort study of transvaginal ultrasonographic screening for ovarian cancer in intermediate to high-risk women from Kentucky. Detection of ovarian malignancy often occurs subsequent to the initial transvaginal sonography (TVS) screen therefore, it is important to offer continued screening to study participants based on our …
- 0 views
- 27 Jul, 2021
- 1 location
Study of STRO-002 an Anti-Folate Receptor Alpha (FolR ) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
- 87 views
- 19 Nov, 2021
- 25 locations
Testing the Combination of Olaparib and Durvalumab Cediranib and Durvalumab Olaparib and Capivasertib and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of …
- 81 views
- 03 Dec, 2021
- 505 locations
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
Advanced technology has enabled radiation oncologists to more accurately and precisely target radiation to areas at risk while maximally sparing healthy tissue. Furthermore, there is growing evidence demonstrating both safety and efficacy for SBRT. We propose that these advantages are translatable to the adjuvant treatment of endometrial cancer. We submit …
- 0 views
- 26 Jan, 2021
- 1 location
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR )
This study, ELU- FR-1, is focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FR) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available. ELU001 is a new …
- 0 views
- 24 Nov, 2021
- 2 locations
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
- 1 views
- 11 Aug, 2021
- 24 locations